WO2002022127A1 - Use of phosphodiesterase inhibitors for the treatment of anorectal disorders - Google Patents

Use of phosphodiesterase inhibitors for the treatment of anorectal disorders Download PDF

Info

Publication number
WO2002022127A1
WO2002022127A1 PCT/GB2000/003510 GB0003510W WO0222127A1 WO 2002022127 A1 WO2002022127 A1 WO 2002022127A1 GB 0003510 W GB0003510 W GB 0003510W WO 0222127 A1 WO0222127 A1 WO 0222127A1
Authority
WO
WIPO (PCT)
Prior art keywords
phosphodiesterase
treatment
present
inhibitors
inhibitor
Prior art date
Application number
PCT/GB2000/003510
Other languages
French (fr)
Inventor
Oliver Jones
Alison Frances Brading
Neil James Mccready Mortensen
Original Assignee
Isis Innovation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Innovation Limited filed Critical Isis Innovation Limited
Priority to AU2000270300A priority Critical patent/AU2000270300A1/en
Priority to PCT/GB2000/003510 priority patent/WO2002022127A1/en
Publication of WO2002022127A1 publication Critical patent/WO2002022127A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Definitions

  • the present invention relates to treatment of anorectal disorders such as anal fissure.
  • Anal fissure can be an acute condition manifested as a longitudinal tear in the epithelium of the anal canal, or a chronic condition in which an acute tear does not heal and an ovoid ulcer forms.
  • the smooth muscle of the anus typically undergoes spasm, causing pain to the affected individual.
  • GTN Glyceryl trinitrate
  • a second class of drug, calcium channel blocking drugs have the advantage that they may be give in oral or topical form.
  • Healing rates are similar for those for GTN, but patients are similarly affected by headache [Cook TA, et al Br. J. Surg. 1999 86: 1269-73].
  • botulinum toxin injections have been used either into the internal sphincter [Maria G et al, N. Engl. J. Med. 1998 338: 217-20], the intersphincteric space [Minguez M et al, Dis. Colon. Rectum. 1999 42: 1016-21.], or the external sphincter [Madalinski M et al, Endoscopy 1999 31 : S63.].
  • This treatment has resulted in higher healing rates in some studies [Brisinda G, et ⁇ /.,.N,.Engl. J. Med...l999 341: 65-9.], but is expensive and can

Abstract

The invention relates to a method for the treatment of an anorectal condition in a mammal, the method comprising administering to a subject in need of such treatment an effective amount of a phosphodiesterase inhibitor, and pharmaceutical preparations for use in this method.

Description

F PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF ANORECTAL DISORDERS
The present invention relates to treatment of anorectal disorders such as anal fissure.
Anal fissure can be an acute condition manifested as a longitudinal tear in the epithelium of the anal canal, or a chronic condition in which an acute tear does not heal and an ovoid ulcer forms. In the untreated condition the smooth muscle of the anus typically undergoes spasm, causing pain to the affected individual.
Historically, the condition has been treated by surgery to overcome the hypertonia either by manual dilation of the anus under general anaesthesia or by lateral internal sphincterotomy. The principal disadvantage of this procedure is a definite incidence of incontinence to flatus and faeces.
Improved understanding of the pharmacology of the anal sphincter [O'Kelly. Ann R Coll Surg Engl 1996 78: 31-8] has resulted in the development of drugs for the treatment of chronic fissures. Glyceryl trinitrate (GTN) paste has been used to treat this condition, [Lund IN, et ah, Br. J. Surg. 1996 83: 1335-1344.], but there are now concerns over long term relapse, headache and tachyphylaxis [Watson SJ, et al., Br. J. Surg. 1996 83: 771-5.]. Moreover, as a topical preparation, it is difficult to regulate dosage, and some patients find the application distasteful which can affect compliance. A second class of drug, calcium channel blocking drugs, have the advantage that they may be give in oral or topical form. Healing rates are similar for those for GTN, but patients are similarly affected by headache [Cook TA, et al Br. J. Surg. 1999 86: 1269-73]. Finally, botulinum toxin injections have been used either into the internal sphincter [Maria G et al, N. Engl. J. Med. 1998 338: 217-20], the intersphincteric space [Minguez M et al, Dis. Colon. Rectum. 1999 42: 1016-21.], or the external sphincter [Madalinski M et al, Endoscopy 1999 31 : S63.]. This treatment has resulted in higher healing rates in some studies [Brisinda G, et α/.,.N,.Engl. J. Med...l999 341: 65-9.], but is expensive and can

Claims

take time to administer. The alpha adrenoceptor antagonists have recently been proposed as an alternative therapy, but they remain incompletely evaluated both in terms of efficacy and side effects.
As such, there is still a need in the art for an effective treatment for anorectal disorders.
The present invention sets out to address this need.
In a first aspect, the present invention provides a method for the treatment of an anorectal condition in a mammal, the method comprising administering to a subject in need of such treatment an effective amount of a phosphodiesterase inhibitor.
We have now discovered that phosphodiesterase inhibitors (PDEI's) are able to cause a dose dependent reduction in the resting muscle tone of the smooth muscle of the anal sphincter which reduces muscle spasm. In this way the pain of anorectal disorders is reduced and healing of such disorders is promoted by the increased blood flow to the diseased area.
The present invention relates to any type of phosphodiesterase inhibitor. Such inhibitors act on phosphodiesterase enzymes, of which eleven families have been characterised to date. Inhibitors of all families tested so far [classes, 1,2,3,4,5,6,8,9,10 and 11] have proven effective in causing relaxation of the internal anal sphincter muscle. Accordingly, the present invention relates to the total range of phosphodiesterase inhibitors, which allows the treatment regime to be extremely flexible because the therapy of the present invention is not limited by the type of naturally occurring phosphodiesterase in the target cells or tissue. Moreover, the specificity of certain PDEI's can allow treatment to be given orally, for example, without generation of significant unwanted effects on other target tissues.
It is known that certain activities of phosphodiesterase enzymes may be related to nervous signals generated by an individual, while others are independent of such host signals. Accordingly, treatments may be developed using appropriate inhibitors to specific phosphodiesterase families which allow co-ordination of the PDEI treatment with the body's own natural nervous signals, or which are completely independent of such signals. Byway of example, the treatment of anal fissure using PDEI's independent of such signals would be desirable to help reduce the resting tone of anal canal 24 hours a day, in order to promote wound healing, hi contrast, in Hirschsprung's disease, a treatment whose effect is dependent upon the nervous signals of the patient would be desirable, to allow muscle relaxation and hence defecation when appropriate for the patient. Accordingly, the present invention also relates to a method for the treatment of an anorectal condition in a mammal as outlined above, wherein the PDEI facilitates an action such as defecation, whilst this action remains under voluntary or nervous control. Thus after administration, the patient is able to defer defecation, for example, until an appropriate time. We prefer that PDEI's which act on class 5 phosphodiesterases, such as sildenafil, are employed in treatments which have an element of voluntary control.
Preferred phosphodiesterase inhibitors are vinpocentine, erythro-9-(2-hydroxy-3- nonyl)adenine ('EHNA'), trequinsin, rolipram, zaprinast, dipyridamole, aminophylline, 4-(3 -butoxy-4-methoxybenzyl)imidazolidin-2-one, caffeine, 1 -(3 -chlorophenylamino)- 4-phenyl-phthalazine, cilostamide, 1,7 dimethylxanthine, etazolate, β- hydroxyethyltheophylline, 3-isobutyl-l-methylxanthine (IBMX), 8-methoxymethyl-3- isobutyl-1-methylxanthine sodium salt, milrinone, papaverine, pentoxifylline, propentofylline, quazinone, tetrahydropapaverine, theobromine, theophylline, trequinsin HCL, enoximone, sildenafil and zardaverine, although any suitable inhibitor may be used in the present invention. Moreover, combinations of PDEI's may also be used.
The anorectal disorders of the present invention include all disorders of the anus and rectum, and also encompass certain disorders of the lower gastrointestinal tract. In particular, it is preferred that the anorectal disorder is anal fissure, haemorrhoids, anismus or Hirschsprung's disease. In these cases there is failure of the internal anal sphincter to relax, which would then be beneficially treated by the phosphodiesterase inhibitors of the present invention. The present invention also relates to pharmaceutical preparations comprising a phosphodiesterase inhibitor of the present invention in combination with a pharmaceutically acceptable carrier.
Examples of pharmaceutical compositions include any solid form (such as tablets, pills, capsule or granules), or liquid form (such as solutions, suspensions or emulsions). The pharmaceutical preparations may be delivered by any delivery means such as oral, topical or parenteral administration, and they may contain the pure phosphodiesterase inhibitor or inhibitor in combination with any carrier or any pharmacologically active compound. Preferably the patient is treated using either an oral dose of the phosphodiesterase inhibitor, a topical treatment such as a paste containing the inhibitor, a suppository, intravenously or by enema.
The correct dosage of the phosphodiesterase inhibitor will vary according to the particular formulation, mode of application, and the particular host being treated. Factors such as age, body weight, sex, diet, time of administration, rate of excretion, condition of the host, drug combinations, reaction sensitivities and severity of the disease are suitably to be taken into account.
The phosphodiesterase inhibitors and compositions of the present invention may be used with other drugs to provide combination therapies. The other drugs may form part of the same composition, or be provided as a separate composition for administration at the same time or a different time. The identity of the other drug is not particularly limited, and suitable candidates include drugs known to treat anorectal disorders at present such as glyceryl trinitrate (GTN), calcium channel blocking drugs, botulinum toxins and adrenocepter antagonists. In combination with PDEI's, levels of these other agents may be reduced such that their current problematic side effects are minimised or rendered clinically tolerable.
Without wishing to be constrained by theory, the use of phosphodiesterase inhibitors in the present invention may serve to improve anorectal disorders by preventing the breakdown of cGMP or cAMP by phosphodiesterase enzymes, thus increasing the level of cGMP/cAMP in cells or tissues. Such an increase in cGMP/cAMP may then assist in smooth muscle relaxation. Accordingly, in addition to treatment of anorectal disorders using phosphodiesterase inhibitors, the present invention also relates to treatments comprising administering phosphodiesterase inhibitors in combination with an agent which increases or stabilises the cGMP or cAMP level in cells or tissues, and compositions comprising such combinations of agents. Suitable agents to increase cGMP or cAMP levels are stimulants of the cylase enzymes which produce these compounds, for example. Whilst this additional treatment is not necessary for the invention to be worked, increased cGMP/cAMP may enhance the therapeutic effect of the invention in certain cases.
The PDEI's of the present invention are also suitable for use in combination with anti- inflammatory agents and analgesics, such as benzocaine, lignocaine, xylocaine, cinchocaine, hydrocortisone, prednisolone, prednisone, adrenalin or methylhydroxybenzoate, for example. Other suitable anti-inflammatory agents and analgesics are well known in the art.
The present invention also relates to the use of a phosphodiesterase inhibitor in the preparation of a medicament for the treatment of an anorectal disorder.
The present invention is now illustrated by the following figures and example, which serve to illustrate the present invention but are not limiting thereon, wherein:
Figure 1 illustrates a dose response curve for vinpocentine and the internal anal sphincter;
Figure 2 indicates the dose response curve for EHNA and the internal anal sphincter;
Figure 3 indicates the dose response curve for trequinsin and the internal anal sphincter;
Figure 4 illustrates the dose response curve for rolipram and the internal anal sphincter;
Figure 5 illustrates the dose response curve for zaprinast and the internal anal sphincter; and
Figure 6 illustrates the dose response curve for dipyridamole and the internal anal sphincter. Example 1 Activity of Phosphodiesterase Inhibitors on internal anal sphincter muscle
Tissue was obtained from three patients (two male; age range 45-56) undergoing either abdominoperineal resection or proctectomy. The tissue was transferred immediately to Krebs solution at 4°C. The epithelium of the anal canal and mucosa of the rectum was removed along with the submucosa. Strips of internal anal sphincter were cut each measuring 1 x 1 x 7 mm, weighing 2 to 8 mg and containing parallel muscle bundles. Fine 5-0 silk ligatures were tied to each end and mounted for isometric tension recording in superfusion organ baths (capacity 0.2 ml). Strips were perfused continuously with Krebs solution (37°C) at a rate of 1 ml/min. Krebs solution contained 120 mM NaCl, 5.9 mM KC1, 15.4 mM NaHCO3, 1.2 mM NaH2PO4, 2.5 mM CaCl2, 1.2 M MgCl2 and 11.5 mM glucose. The Krebs solution was equilibrated with 97% oxygen and 3% carbon dioxide to maintain the pH at 7.4 ± 0.05. This apparatus allowed six strips to be studied simultaneously. The strips were initially loaded with 1 g tension and allowed to equilibrate for at least 90 minutes. Tension was measured by Pioden dynamometer UFl transducers (Pioden Controls, Canterbury, UK) and recorded on a six channel Tekman 900 pen recorder (Tekman Electronics, Leamington Spa, UK).
The tension present in strips perfused with calcium free solution (CaC12 replaced isosmotically with MgCl2, and 0.5 mM ethylene glycol tetraacetic acid; Sigma Chemical Co, Poole, UK) was regarded as zero tension. This was subtracted from observed tension to give actual tension. Increasing concentrations of drugs were added for 15 minute periods. Drugs used were vinpocentine, EHNA hydrochloride, trequinsin, rolipram, zaprinast and dipyridamole; Sigma Chemical Co, Poole, UK.
Strips from the internal anal sphincter developed spontaneous tone and myogenic activity. All phosphodiesterase inhibitors caused a dose dependent reduction in resting tone in strips from the internal anal sphincter. The maximum reduction in tone for each type of PDE inhibitor is shown in table 1.
Selective for Maximum percentage IC50 (μM)
PDE type reduction in tone (±SE)
Vinpocentine 1 44.1 (8.2) 4.9
EHNA hydrochloride 2 46.9 (5.8) 25
Trequinsin 3 56.9 (14.3) 0.0013
Rolipram 4 59.4 (6.3) 7.8
Zaprinast 5/6/9 73.9 (4.4) 0.64
Dipyridamole 5/6/8/10/11 76.1 (6.6) 5.2
Table 1 : Maximum reduction in tone for PDE inhibitors with different subtype selectivity. The IC50 figure shown are those given in manufacturers data sheets and represent values from in vitro assays.
Dose response curves for the different PDE inhibitors on the internal anal sphincter are shown in Figures 1-6. All inhibitors caused profound reductions both in tone and spontaneous activity.
Claims
1 A method for the treatment of an anorectal condition in a mammal, the method comprising administering to a subject in need of such treatment an effective amount of a phosphodiesterase inhibitor.
2 A method according to claim 1, wherein the phosphodiesterase inhibitor is selected from the list consisting of vinpocentine, EHMA, trequinsin, rolipram, zaprinast and dipyridamole, vinpocentine, erythro-9-(2-hydroxy-3-nonyl)adenine ['EHNA'], trequinsin, rolipram, zaprinast, dipyridamole, aminophylline, 4-(3-butoxy-4- methoxybenzyl)imidazolidin-2-one, caffeine, 1 -(3 -chlorophenylamino)-4-phenyl- phthalazine, cilostamide, 1,7 dimethylxanthine, etazolate, β-hydroxyethyltheophylline, 3-isobutyl- 1 -methylxanthine [IBMX] , 8-methoxymethyl-3 -isobutyl- 1 -methylxanthine sodium salt, milrinone, papaverine, pentoxifylline, propentofylline, quazinone, tetrahydropapaverine, theobromine, theophylline, trequinsin HCL, enoximone, sildenafil and zardaverine.
3 A method according to claim 1 or 2, wherein the anorectal disorder of the present invention is anal fissure, haemorrhoids, anismus or Hirschsprung's disease.
4 A method according to any preceding claim, wherein more than one phosphodiesterase inhibitor is administered.
5 A method according to any preceding claim, additionally comprising administration of one or more of glyceryl trinitrate (GTN), a calcium channel blocking drug, botulinum toxin or an adrenocepter antagonist.
6 A method according to any preceding claim, additionally comprising administration of an agent which increases or stabilises the cGMP or cAMP level in cells or tissues of the subject. 7 A method according to any preceding claim additionally comprising administration of an anti-inflammatory agent or analgesic.
8 A method according to any preceding claim, wherein the administration is by oral or topical delivery, intravenously, by suppository or enema.
9 A method according to any preceding claim, wherein the phosphodiesterase inhibitor facilitates an effect on smooth muscle, the effect being under voluntary or nervous control of the subject.
10 A method according to claim 9, wherein the phosphodiesterase inhibitor is an inhibitor of class 5 phosphodiesterases.
11 A pharmaceutical preparation for use in the method of any preceding claim comprising a phosphodiesterase inhibitor in combination with a pharmaceutically acceptable carrier.
12 A pharmaceutical preparation according to claim 11 comprising more than one phosphodiesterase inhibitor.
13 A pharmaceutical preparation according to claim 11 or 12 additionally comprising glyceryl trinitrate (GTN), a calcium channel blocking drug, botulinum toxin or an adrenocepter antagonist.
14 A pharmaceutical preparation according to claim 11, 12 or 13 additionally comprising an agent which increases or stabilises the cGMP or cAMP level in cells or tissues of the subject.
15 A pharmaceutical preparation according to any of claims 11-14 additionally comprising an anti-inflammatory agent or analgesic. 16 Use of a phosphodiesterase inhibitor in the preparation of a medicament for the treatment of an anorectal disorder.
PCT/GB2000/003510 2000-09-13 2000-09-13 Use of phosphodiesterase inhibitors for the treatment of anorectal disorders WO2002022127A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2000270300A AU2000270300A1 (en) 2000-09-13 2000-09-13 Use of phosphodiesterase inhibitors for the treatment of anorectal disorders
PCT/GB2000/003510 WO2002022127A1 (en) 2000-09-13 2000-09-13 Use of phosphodiesterase inhibitors for the treatment of anorectal disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2000/003510 WO2002022127A1 (en) 2000-09-13 2000-09-13 Use of phosphodiesterase inhibitors for the treatment of anorectal disorders

Publications (1)

Publication Number Publication Date
WO2002022127A1 true WO2002022127A1 (en) 2002-03-21

Family

ID=9885671

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/003510 WO2002022127A1 (en) 2000-09-13 2000-09-13 Use of phosphodiesterase inhibitors for the treatment of anorectal disorders

Country Status (2)

Country Link
AU (1) AU2000270300A1 (en)
WO (1) WO2002022127A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007140181A2 (en) * 2006-05-26 2007-12-06 King Pharmaceuticals Research And Development, Inc. Combination therapy comprising an adenosine uptake inhibitor and a non-selective adenosine receptor antagonist
CN101744822B (en) * 2008-12-14 2011-03-23 鲁南制药集团股份有限公司 Medicinal composition for treating hemorrhoids
US7915265B2 (en) 2001-10-05 2011-03-29 Zalicus Inc. Combinations for the treatment of immunoinflammatory disorders
US8080553B2 (en) 2003-10-15 2011-12-20 Zalicus Inc. Methods and reagents for the treatment of immunoinflammatory disorders

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486436A (en) * 1982-07-22 1984-12-04 Analgesic Associates Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
DE3800301A1 (en) * 1988-01-08 1989-07-20 Rudolf Leitz Procain-containing ointment and its use
RO103863B1 (en) * 1989-03-22 1992-04-26 Institutul De Cercetari Chimico-Farmaceutice Suppositories with anti-spastic and scar healing action
US5145852A (en) * 1989-07-11 1992-09-08 Ronald Virag Vaso-active medicament to treat impotence
US5552267A (en) * 1992-04-03 1996-09-03 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation
WO1998019672A1 (en) * 1996-11-01 1998-05-14 Nitromed Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
WO1998037894A1 (en) * 1997-02-28 1998-09-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Synergistic combination of pde inhibitors and adenylate cyclase agonists or guanyl cyclyse agonists
WO1998041232A2 (en) * 1997-03-18 1998-09-24 Basf Aktiengesellschaft Compositions for modulating responsiveness to corticosteroids
WO1999030697A2 (en) * 1997-12-16 1999-06-24 Pfizer Products Inc. Combination effective for the treatment of impotence
RU2144354C1 (en) * 1997-10-27 2000-01-20 Козырев Валентин Архипович Method of nocturnal enuresis treatment
WO2000024745A1 (en) * 1998-10-23 2000-05-04 Pfizer Limited PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION
US6060501A (en) * 1994-06-02 2000-05-09 Schering Aktiengesellschaft Combined treatment of multiple sclerosis
WO2000035434A2 (en) * 1998-12-14 2000-06-22 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
WO2000042018A1 (en) * 1999-01-15 2000-07-20 Byk Gulden Lomberg Chemische Fabrik Gmbh Polysubstituted 6-phenylphenanthridines with pde-iv inhibiting activity

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486436A (en) * 1982-07-22 1984-12-04 Analgesic Associates Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
DE3800301A1 (en) * 1988-01-08 1989-07-20 Rudolf Leitz Procain-containing ointment and its use
RO103863B1 (en) * 1989-03-22 1992-04-26 Institutul De Cercetari Chimico-Farmaceutice Suppositories with anti-spastic and scar healing action
US5145852A (en) * 1989-07-11 1992-09-08 Ronald Virag Vaso-active medicament to treat impotence
US5552267A (en) * 1992-04-03 1996-09-03 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation
US6060501A (en) * 1994-06-02 2000-05-09 Schering Aktiengesellschaft Combined treatment of multiple sclerosis
WO1998019672A1 (en) * 1996-11-01 1998-05-14 Nitromed Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
WO1998037894A1 (en) * 1997-02-28 1998-09-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Synergistic combination of pde inhibitors and adenylate cyclase agonists or guanyl cyclyse agonists
WO1998041232A2 (en) * 1997-03-18 1998-09-24 Basf Aktiengesellschaft Compositions for modulating responsiveness to corticosteroids
RU2144354C1 (en) * 1997-10-27 2000-01-20 Козырев Валентин Архипович Method of nocturnal enuresis treatment
WO1999030697A2 (en) * 1997-12-16 1999-06-24 Pfizer Products Inc. Combination effective for the treatment of impotence
WO2000024745A1 (en) * 1998-10-23 2000-05-04 Pfizer Limited PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION
WO2000035434A2 (en) * 1998-12-14 2000-06-22 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
WO2000042018A1 (en) * 1999-01-15 2000-07-20 Byk Gulden Lomberg Chemische Fabrik Gmbh Polysubstituted 6-phenylphenanthridines with pde-iv inhibiting activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; IONESCU, MIOARA ET AL: "Formulation of antispastic and cicatrizant suppositories", XP002170195, retrieved from STN Database accession no. 121:263690 *
DATABASE WPI Week 200051, Derwent World Patents Index; AN 2000-557073, XP002170196, KOZYREV V.A.: "Method of nocturnal enuresis treatment" *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7915265B2 (en) 2001-10-05 2011-03-29 Zalicus Inc. Combinations for the treatment of immunoinflammatory disorders
US8080553B2 (en) 2003-10-15 2011-12-20 Zalicus Inc. Methods and reagents for the treatment of immunoinflammatory disorders
WO2007140181A2 (en) * 2006-05-26 2007-12-06 King Pharmaceuticals Research And Development, Inc. Combination therapy comprising an adenosine uptake inhibitor and a non-selective adenosine receptor antagonist
WO2007140181A3 (en) * 2006-05-26 2008-08-14 King Pharmaceuticals Res & Dev Combination therapy comprising an adenosine uptake inhibitor and a non-selective adenosine receptor antagonist
CN101744822B (en) * 2008-12-14 2011-03-23 鲁南制药集团股份有限公司 Medicinal composition for treating hemorrhoids

Also Published As

Publication number Publication date
AU2000270300A1 (en) 2002-03-26

Similar Documents

Publication Publication Date Title
US7919484B2 (en) Combination therapy
ES2202352T3 (en) DERIVATIVES OF 5- (2-IMIDAZOLINYLAMINE) BENCIMIDAZOL, ITS PREPARATION AND USE AS AGONISTS OF ALFA-2 ADRENORRECEPTORS.
CN104662007B (en) Cystathionine gamma lyase (CSE) inhibitor
JP2018501276A (en) ACC inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease
US20050014783A1 (en) Use of Rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
JP2001517639A (en) Use of a combination comprising a non-sedating antihistamine and an α-adrenergic agonist for the topical treatment of rhinitis / conjunctivitis and cold, cold-like and / or epidemic cold symptoms
JP2004525179A (en) Treatment of type II diabetes with dipeptidyl peptidase IV inhibitors
JPS61277620A (en) Dysuria therapy
US20070066597A1 (en) Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders
RU2290929C2 (en) Pharmaceutical composition for treatment of interstitial cystitis
EP1843765A2 (en) The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
JP4637571B2 (en) Compositions and methods for treating lower urinary tract dysfunction with delta opioid receptor agonists
US20030176421A1 (en) Prokinetic agents for treating gastric hypomotility and related disorders
JPH10158169A (en) Pharmaceutical preparation containing trospium chloride, its preparation and use thereof
JP2000198734A (en) Prokinetic agent for treating gastric hypomotility and related disease
JPWO2006118212A1 (en) Preventive and therapeutic agent for pancreatitis
WO2002022127A1 (en) Use of phosphodiesterase inhibitors for the treatment of anorectal disorders
US20110230407A1 (en) Hepatocyte growth factor pathway activators in demyelinating diseases and central nervous system trauma
US7879898B1 (en) Hepatocyte growth factor pathway activators in chronic obstructive pulmonary disease
JP2005516977A (en) Use of 4- (2-fluorophenyl) -6-methyl-2- (1-piperazinyl) thieno (2,3-D-pyrimidine) in the treatment of urinary incontinence
JP2004523559A (en) Methods for treating irritable bowel syndrome and functional gastroenteropathy
WO1998037887A1 (en) Anticancer composition comprising a diaminotrifluoromethylpyridine derivative
JP4686704B2 (en) Aneurysm prophylactic and / or therapeutic agent
KR100863758B1 (en) Compositions and methods for the treatment of anorectal disorders
JP2000026313A (en) Suppressant for enterokinesis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP